The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – a four-arm randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – a four-arm randomized controlled trial. / Sandby, Karoline; Magkos, Faidon; Chabanova, Elizaveta; Petersen, Esben T.; Krarup, Thure; Bertram, Hanne C.; Kristiansen, Karsten; Geiker, Nina R.W.

I: Clinical Nutrition, Bind 43, Nr. 2, 2024, s. 534-542.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Sandby, K, Magkos, F, Chabanova, E, Petersen, ET, Krarup, T, Bertram, HC, Kristiansen, K & Geiker, NRW 2024, 'The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – a four-arm randomized controlled trial', Clinical Nutrition, bind 43, nr. 2, s. 534-542. https://doi.org/10.1016/j.clnu.2023.12.018

APA

Sandby, K., Magkos, F., Chabanova, E., Petersen, E. T., Krarup, T., Bertram, H. C., Kristiansen, K., & Geiker, N. R. W. (2024). The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – a four-arm randomized controlled trial. Clinical Nutrition, 43(2), 534-542. https://doi.org/10.1016/j.clnu.2023.12.018

Vancouver

Sandby K, Magkos F, Chabanova E, Petersen ET, Krarup T, Bertram HC o.a. The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – a four-arm randomized controlled trial. Clinical Nutrition. 2024;43(2):534-542. https://doi.org/10.1016/j.clnu.2023.12.018

Author

Sandby, Karoline ; Magkos, Faidon ; Chabanova, Elizaveta ; Petersen, Esben T. ; Krarup, Thure ; Bertram, Hanne C. ; Kristiansen, Karsten ; Geiker, Nina R.W. / The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – a four-arm randomized controlled trial. I: Clinical Nutrition. 2024 ; Bind 43, Nr. 2. s. 534-542.

Bibtex

@article{fe3bae80f919458288ba3f0689d5c063,
title = "The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – a four-arm randomized controlled trial",
abstract = "Background & aims: In recent years, epidemiological studies have reported links between the consumption of fermented dairy products, such as yogurt, and health; however, evidence from human intervention trials is scarce and inconsistent. We aimed to investigate the effect of consumption of four different types of dairy products (two fermented and two non-fermented) on liver fat (primary outcome) and metabolic risk markers in males with abdominal obesity. Methods: In this parallel randomized controlled trial with four arms, 100 males aged 30–70 years, with body mass index 28.0–45.0 kg/m2, and waist circumference ≥102 cm underwent a 16-weeks intervention where they were instructed to consume 400 g/day of either milk, yogurt, heat-treated yogurt, or acidified milk as part of their habitual diet. Liver fat was measured by magnetic resonance imaging. Results: In the complete case analyses (n = 80), no effects of the intervention or differences between groups were detected in anthropometry or body composition including liver fat. Moreover, no effects were detected in inflammatory markers. Main effects of time were detected in blood pressure (decrease; P < 0.001), insulin (decrease; P < 0.001), C-peptide (decrease; P = 0.040), homeostatic model assessment for insulin resistance (decrease; P < 0.001), total cholesterol (decrease; P = 0.016), low-density lipoprotein (decrease; P = 0.033), high-density lipoprotein (decrease; P = 0.006), and alanine transaminase (decrease; P = 0.019). Interactions between group and time failed to reach significance. Conclusions: In conclusion, findings from our study do not confirm that fermented yogurt products are superior in reducing liver fat or improving metabolic risk markers compared to non-fermented milk products. In fact, all intervention products (both fermented yogurt products and non-fermented milk products) did not affect liver fat and caused largely similar modest favorable changes in some metabolic risk markers. The study was registered at www.clinicaltrials.gov (# NCT04755530).",
keywords = "Fermentation, Intrahepatic lipid, Milk, Steatosis, Yogurt",
author = "Karoline Sandby and Faidon Magkos and Elizaveta Chabanova and Petersen, {Esben T.} and Thure Krarup and Bertram, {Hanne C.} and Karsten Kristiansen and Geiker, {Nina R.W.}",
note = "Publisher Copyright: {\textcopyright} 2024 The Authors",
year = "2024",
doi = "10.1016/j.clnu.2023.12.018",
language = "English",
volume = "43",
pages = "534--542",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - The effect of dairy products on liver fat and metabolic risk markers in males with abdominal obesity – a four-arm randomized controlled trial

AU - Sandby, Karoline

AU - Magkos, Faidon

AU - Chabanova, Elizaveta

AU - Petersen, Esben T.

AU - Krarup, Thure

AU - Bertram, Hanne C.

AU - Kristiansen, Karsten

AU - Geiker, Nina R.W.

N1 - Publisher Copyright: © 2024 The Authors

PY - 2024

Y1 - 2024

N2 - Background & aims: In recent years, epidemiological studies have reported links between the consumption of fermented dairy products, such as yogurt, and health; however, evidence from human intervention trials is scarce and inconsistent. We aimed to investigate the effect of consumption of four different types of dairy products (two fermented and two non-fermented) on liver fat (primary outcome) and metabolic risk markers in males with abdominal obesity. Methods: In this parallel randomized controlled trial with four arms, 100 males aged 30–70 years, with body mass index 28.0–45.0 kg/m2, and waist circumference ≥102 cm underwent a 16-weeks intervention where they were instructed to consume 400 g/day of either milk, yogurt, heat-treated yogurt, or acidified milk as part of their habitual diet. Liver fat was measured by magnetic resonance imaging. Results: In the complete case analyses (n = 80), no effects of the intervention or differences between groups were detected in anthropometry or body composition including liver fat. Moreover, no effects were detected in inflammatory markers. Main effects of time were detected in blood pressure (decrease; P < 0.001), insulin (decrease; P < 0.001), C-peptide (decrease; P = 0.040), homeostatic model assessment for insulin resistance (decrease; P < 0.001), total cholesterol (decrease; P = 0.016), low-density lipoprotein (decrease; P = 0.033), high-density lipoprotein (decrease; P = 0.006), and alanine transaminase (decrease; P = 0.019). Interactions between group and time failed to reach significance. Conclusions: In conclusion, findings from our study do not confirm that fermented yogurt products are superior in reducing liver fat or improving metabolic risk markers compared to non-fermented milk products. In fact, all intervention products (both fermented yogurt products and non-fermented milk products) did not affect liver fat and caused largely similar modest favorable changes in some metabolic risk markers. The study was registered at www.clinicaltrials.gov (# NCT04755530).

AB - Background & aims: In recent years, epidemiological studies have reported links between the consumption of fermented dairy products, such as yogurt, and health; however, evidence from human intervention trials is scarce and inconsistent. We aimed to investigate the effect of consumption of four different types of dairy products (two fermented and two non-fermented) on liver fat (primary outcome) and metabolic risk markers in males with abdominal obesity. Methods: In this parallel randomized controlled trial with four arms, 100 males aged 30–70 years, with body mass index 28.0–45.0 kg/m2, and waist circumference ≥102 cm underwent a 16-weeks intervention where they were instructed to consume 400 g/day of either milk, yogurt, heat-treated yogurt, or acidified milk as part of their habitual diet. Liver fat was measured by magnetic resonance imaging. Results: In the complete case analyses (n = 80), no effects of the intervention or differences between groups were detected in anthropometry or body composition including liver fat. Moreover, no effects were detected in inflammatory markers. Main effects of time were detected in blood pressure (decrease; P < 0.001), insulin (decrease; P < 0.001), C-peptide (decrease; P = 0.040), homeostatic model assessment for insulin resistance (decrease; P < 0.001), total cholesterol (decrease; P = 0.016), low-density lipoprotein (decrease; P = 0.033), high-density lipoprotein (decrease; P = 0.006), and alanine transaminase (decrease; P = 0.019). Interactions between group and time failed to reach significance. Conclusions: In conclusion, findings from our study do not confirm that fermented yogurt products are superior in reducing liver fat or improving metabolic risk markers compared to non-fermented milk products. In fact, all intervention products (both fermented yogurt products and non-fermented milk products) did not affect liver fat and caused largely similar modest favorable changes in some metabolic risk markers. The study was registered at www.clinicaltrials.gov (# NCT04755530).

KW - Fermentation

KW - Intrahepatic lipid

KW - Milk

KW - Steatosis

KW - Yogurt

U2 - 10.1016/j.clnu.2023.12.018

DO - 10.1016/j.clnu.2023.12.018

M3 - Journal article

C2 - 38232682

AN - SCOPUS:85182790525

VL - 43

SP - 534

EP - 542

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 2

ER -

ID: 387256205